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We prospectively studied 156 patients with a diagnosis of community-acquired pneumonia requiring admis-
sion. Several respiratory specimens were obtained for the detection of Chlamydia pneumoniae by cell culture and
PCR. Three serum samples were obtained from each patient. Serological diagnosis of a C. pneumoniae infection
was determined by the microimmunofluorescence (MIF) test, the complement fixation (CF) test, and recom-
binant lipopolysaccharide (LPS) enzyme-linked immunosorbent assay (ELISA; referred to as the rDNA LPS
ELISA). Twenty-three patients (15%) had serological results compatible with acute C. pneumoniae infection;
nine (39%) of these subjects were C. pneumoniae PCR positive. Twenty-two patients (14%) had positive PCR
results without serological evidence of an acute C. pneumoniae infection. An attempt was made to calculate the
sensitivities and specificities of the MIF test, rDNA LPS ELISA, and PCR for the diagnosis of chlamydial
community-acquired pneumonia. Several “gold standards” were defined. Generally, the sensitivities of the
rDNA LPS ELISA and MIF were comparable, while the sensitivity of the CF test was shown to be very low.
Independent of the gold standard used, the best PCR results were obtained with nasopharyngeal specimens.
However, the predictive value of a positive C. pneumoniae PCR result for patients with community-acquired
pneumonia remains unknown and may be low. Although a widely accepted gold standard is still lacking, the
rDNA LPS ELISA may currently be the preferred tool for diagnosing acute respiratory Chlamydia infections
in routine clinical practice. However, the MIF test remains the method of choice for determining the prevalence
of C. pneumoniae infections in a given community.
Most respiratory infections caused by Chlamydia pneumo-
niae are mild or asymptomatic (1, 9, 26, 42). Similar to Myco-
plasma infections, C. pneumoniae can cause recurrent or sec-
ondary lower respiratory tract infections, even though antibody
due to previous infection are detectable in serum (1). Infection
with C. pneumoniae occurs worldwide, resulting in a 40 to 90%
prevalence of serum antibody to the species (3, 18, 34, 48).
C. pneumoniae has been associated with both epidemic and
endemic occurrences of acute respiratory disease and is be-
lieved to be responsible for 6 to 20% of all community-ac-
quired pneumonias (CAPs) (1, 13, 21, 28, 38, 41). Diagnosis of
C. pneumoniae infection is preferably based on the isolation of
the organism from respiratory specimens, PCR, and/or serol-
ogy (20, 51). However, isolation of C. pneumoniae by cell
culture remains difficult and its sensitivity is unknown. Subse-
quently, culture tests are not available in routine laboratories.
Also, PCR requires specially trained, experienced personnel
and is not yet commercially available. Therefore, serology is
currently the tool most often applied for the routine diagnosis
of acute C. pneumoniae infection. The commercially available
serological tests include the complement fixation (CF) test, the
microimmunofluorescence (MIF) test, and the enzyme-linked
immunosorbent assay (ELISA). The CF test has traditionally
been used to diagnose chlamydial respiratory infections (32,
39). This assay uses an enriched lipopolysaccharide (LPS)
antigen derived from Chlamydia psittaci for the detection of
Chlamydia genus-specific antibodies. CF assays are technically
demanding, and no information is obtained about the immu-
noglobulin classes involved in the reaction. The “gold stan-
dard” in C. pneumoniae serology at this moment is the MIF
test (12, 30, 40). Chlamydia elementary bodies, which are the
infective cell forms of Chlamydia, are used as antigen in the
MIF test. This test is supposed to be species specific and can
differentiate between immunoglobulin G (IgG), IgM, and IgA
antibodies (39, 44).
We evaluated a commercially available recombinant LPS
ELISA (rDNA LPS ELISA), the MIF test, PCR, and culture
for the diagnosis of CAP caused by C. pneumoniae. In addition,
we sought to evaluate the usefulness of the rDNA LPS assay to
determine the seroprevalence of C. pneumoniae.
MATERIALS AND METHODS
Patients. The study population included four different groups of patients. The
first group consisted of 1,104 blood donors visiting the Red Cross Blood Trans-
fusion Center, Tilburg, The Netherlands. One serum sample from each blood
donor was stored at 280°C prior to use in this study. The donors’ ages ranged
from 18 to 68 years, with a median of 40 years. The second group consisted of 271
patients with chronic obstructive pulmonary diseases (COPDs) attending the
outpatient clinic of pulmonary diseases from the St. Antonius Hospital, Nieu-
wegein, The Netherlands. The patients’ ages ranged from 43 to 88 years, with a
median of 67 years. The third group consisted of 156 prospectively studied
patients who were consecutively admitted to the same St. Antonius Hospital with
CAP. The diagnosis was based on clinical signs and symptoms and new or
progressive radiographic changes consistent with pneumonia (10). The patients’
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ages ranged from 20 to 93 years, with a median of 68 years. The fourth group
consisted of 40 other patients with a recent Mycoplasma pneumoniae infection, as
indicated by rising CF antibody titers or by a positive IgM immunofluorescence
reaction (serum samples kindly provided in part by R. J. A. Diepersloot, Dia-
konessen Hospital, Utrecht, The Netherlands).
Clinical specimens. Serum samples were collected by standard procedures and
were stored at 280°C prior to processing. From each patient with CAP, naso-
pharyngeal and throat specimens were collected with sterile cotton-tipped alu-
minum-shafted swabs and were suspended in 1.5 ml of Chlamydia transport
medium (0.2 M sucrose phosphate [2SP]). A throat wash sample was obtained
with 10 ml of phosphate-buffered saline. Sputum samples were collected by
standard procedures. The first serum sample was obtained within the first 24 h of
enrollment. A second (convalescent-phase) serum sample was obtained from all
patients 10 days after enrollment. A third serum sample was obtained from 142
patients (91%) after 30 days.
Laboratory assays for C. pneumoniae. (i) Culture. Culture for C. pneumoniae
was done as described previously (44). Briefly, Buffalo Green Monkey (BGM)
cells (St. Joseph Hospital, PAMM, Veldhoven, The Netherlands) (45) were
seeded into 24-well tissue culture plates (Costar Europe Ltd.), and the plates
were incubated at 35°C with 5% CO2 in a fully humidified cabinet. All cell
monolayers were examined on the day of inoculation for confluent growth. For
each experiment, a patient’s sample was inoculated into two wells of a 24-well
cell culture plate and one flat-bottom tube. After inoculation, the cell culture
plates were centrifuged at 900 3 g and 25°C for 60 min and were subsequently
incubated with fresh medium containing cycloheximide (0.6 mg/liter; Sigma
Chemical Company, St. Louis, Mo.). After 3 days, the 24-well plates were aspi-
rated and fixed with methanol (Merck, Darmstadt, Germany). The fixed mono-
layers were rinsed once with phosphate-buffered saline and stained by the fluo-
rescent-antibody technique with Chlamydia genus-specific mouse monoclonal
antibody (kindly provided by J. M. Ossewaarde, National Institute of Public
Health and Environmental Protection, Bilthoven, The Netherlands). The con-
tents of the inoculated flat-bottom tubes were passed onto fresh monolayers and
were reincubated as described above. This procedure was repeated once more. In
each culture series, C. pneumoniae TW-183 was included in parallel as a positive
control. Positive cultures were stained with C. pneumoniae-specific mouse mono-
clonal antibodies (Washington Research Foundation, Seattle, Wash.). Rabbit
anti-mouse immunoglobulin labeled with fluorescein isothiocyanate (Dako A/S,
Glostrup, Denmark) was used as a conjugate. Evans Blue (0.05%; Sigma Chem-
ical Company) was used as a counterstain.
(ii) PCR. Two hundred microliters of a nasopharyngeal or a throat swab
specimen or 1.0 ml of a throat wash specimen and bronchoalveolar lavage fluid
were transferred to a sterile tube and centrifuged at 15,000 3 g for 30 min.
Sputum samples were suspended in 1.5 ml of 2SP transport medium. One
hundred microliters of the suspended sputum sample was transferred to a sterile
tube, and the tube was centrifuged at 15,000 3 g for 30 min. The sediment was
incubated with a solid carrier (Celite) and a guanidinium thiocyanate-containing
lysis buffer. Nucleic acids (NA) were bound to the carrier, which was rapidly
sedimented by centrifugation. The sedimented complexes were washed once with
a guanidinium thiocyanate-containing washing buffer, once with 70% ethanol,
and once with acetone. Complexes were dried and the NA were subsequently
eluted in 55 ml of aqueous solution at 37°C for 30 min. The isolated NA were
removed from the solid carrier by centrifugation (5). Amplification by PCR and
analysis of the amplified products were performed as described by Campbell et
al. (8). Briefly, PCR amplification was performed with 8 ml of isolated DNA in
a 100-ml reaction mixture containing 20 mM (NH4)2SO4, 75 mM Tris-HCl (pH
9.0), 0.01% Tween 20, 0.2 mM deoxynucleoside triphosphates, 50 pmol of prim-
ers, and 0.2 U of Thermoperfect Taq polymerase (Integra Biosciences A. G.,
Wallisellen, Switzerland). A C. pneumoniae species-specific primer set was used;
this primer set amplifies a 437-bp fragment and consists of the following primers:
forward primer HL-1 (59-GTTGTTCATGAAGGCCTACT-39) and reverse
primer HR-1 (59-TGCATAACCTACGGTGTGTT-39). The PCR products (20
ml) were analyzed by electrophoresis on a 1.5% agarose gel stained with ethidium
bromide. Electrophoretic transfer transferred DNA from agarose to Hybond
plus nylon filters (Amersham International plc, Amersham, United Kingdom).
The PCR products were analyzed with a C. pneumoniae-specific probe, probe
HM-1 (59-GTGTCATTCGCCAAGGTTAA-39). The ECL 39 oligolabeling and
detection system (Amersham International, plc) was used for the detection of the
PCR products. A 10-fold serial dilution of a C. pneumoniae stock solution (109
target DNA copies per ml) was incorporated into each amplification. One neg-
ative control (pooled cervical specimens suspended in 2SP) was incorporated
every 10 amplifications. All PCR-positive results were confirmed by repeat DNA
isolation and amplification of the original specimen. Separate rooms were used
for the different steps of the PCR, and the recommendations of Kwok and
Higuchi (33) were used to prevent DNA carryover contamination.
(iii) MIF assay. The MIF assay described before (44) was used to measure
C. pneumoniae-specific IgG, IgM, and IgA antibodies. Briefly, purified C. pneu-
moniae elementary antibodies (strain AR 39; Washington Research Foundation)
were used to detect IgG, IgM, and IgA antibodies to C. pneumoniae. Prior to the
IgM determinations, IgG absorption was performed (44). The prevalence of
C. pneumoniae-specific IgG, IgM, and IgA antibodies was based on the presence
of IgG at titers of $1:32, IgM at titers of $1:16, and IgA at titers of $1:32,
respectively. Diagnosis of an acute C. pneumoniae infection was based on the
following criteria: the presence of C. pneumoniae-specific IgM in either acute- or
convalescent-phase serum or a fourfold or greater increase in the C. pneumoniae-
specific IgG and/or IgA antibody titer between the acute- and convalescent-
phase serum samples (44).
(iv) CF test. The CF test was used to measure Chlamydia genus-specific an-
tibodies with C. psittaci antigen (Virion International Distribution Ltd., Chan,
Switzerland). A fourfold or greater increase in titer was considered definitive
etiologic evidence of infection.
(v) ELISA. Chlamydia-specific IgG, IgM, and IgA antibodies were detected by
an rDNA LPS ELISA (Medac GmbH, Hamburg, Germany). This ELISA in-
cludes a chemically pure structure of a recombinant LPS which contains a genus-
specific epitope of the Chlamydia spp. pathogenic for humans (6, 7, 25). Initial
serum dilutions for the detection of IgG, IgM, and IgA were 1:100, 1:50, and
1:50, respectively. Prior to the IgM determinations, IgG absorption was per-
formed (44). Sera with optical density values exceeding 2.5 were retested with a
1:4 predilution. A twofold serially diluted standard serum sample was used to
calculate the log2 titer of the patients’ samples. The IgG, IgM, and IgA cutoff
values were calculated as prescribed by the manufacturer. The prevalence of
Chlamydia IgG, IgM, and IgA antibodies was based on the following criteria:
greater than or equal to the calculated cutoff 3 1.10, greater than or equal to the
calculated cutoff 3 1.15, and greater than or equal to the calculated cutoff 3
1.10, respectively. Serological diagnosis of an acute Chlamydia infection was
based on the ELISA results by using the following criteria: a threefold or greater
increase in Chlamydia-specific IgG or IgA antibody titer, a twofold or greater
change in the specific IgM titer, or a twofold increase in the specific IgG antibody
titer in combination with a twofold increase in the specific IgA antibody titer
(47).
RESULTS
Seroprevalence. The prevalences of Chlamydia-specific IgG
antibodies in the healthy blood donor group and the COPD
patient group were 29.4 and 53.1%, respectively, as determined
by the rDNA LPS ELISA (P , 0.0001) (Table 1). Significantly
higher seroprevalences were observed if the C. pneumoniae
MIF assay was used (Table 1). The seroprevalence by the MIF
assay was the same for healthy blood donors and COPD pa-
tients (71 and 72%, respectively). By using the MIF assay as
the gold standard, the sensitivity and specificity of the rDNA
LPS ELISA for determination of serological evidence of a
C. pneumoniae infection in the past thus depended on the
population tested (Table 1). For the healthy blood donor
group the sensitivity and specificity were 33.5 and 80.5%, re-
spectively, while for the patients with COPD, the sensitivity
and specificity were 64.1 and 75.0%, respectively. A similar
trend was observed when calculating the negative predictive
value (NPV) and the positive predictive value (PPV) (Table 1).






by the following: rDNA LPS ELISA
a
MIF assay rDNA LPS ELISA Sensitivity (%) Specificity (%) NPV (%) PPV (%)
Blood donors 1,104 71.2 29.4 33.5 80.5 32.9 80.9
COPD patients 271 72.0 53.1b 64.1 75.0 44.9 86.8
a The MIF assay was used as the gold standard.
b P , 0.0001 compared to blood donors.
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Acute C. pneumoniae infections. It was possible to make a
diagnosis of C. pneumoniae CAP for 45 patients (29%). Twen-
ty-three patients (15%) had serological results (MIF assay and/
or rDNA LPS ELISA) indicating acute C. pneumoniae in-
fection (seroresponders). Nine of these subjects (39%) were
C. pneumoniae PCR positive. In addition, 22 (14%) patients
had positive PCR results without serological evidence of acute
C. pneumoniae infection (serononresponders). In 14 of 15
(93%) patients with MIF assay results indicative of acute
C. pneumoniae infection, the diagnosis was supported by the
rDNA LPS ELISA and/or the PCR test results. Six patients
had serological results indicative of an acute infection only by
the rDNA LPS ELISA (Fig. 1). Only one patient had positive
C. pneumoniae culture results which were confirmed by PCR,
MIF assay, and ELISA (data not shown in Fig. 1). Of those
that responded serologically, only two patients had CF test
results indicative of an acute chlamydial infection.
For 14 of 23 (61%) seroresponders, C. pneumoniae infection
was associated with other etiologies. In six patients, Streptococ-
cus pneumoniae infection was also diagnosed. Other frequent
concomitant microorganisms were Haemophilus influenzae,
M. pneumoniae, and Legionella pneumophila. Although coin-
fection was observed among serononresponders as well, asso-
ciations with other agents were found significantly more often
in seroresponders than in serononresponders (61 and 23%,
respectively; P 5 0.017).
No clear difference in the clinical presentation was observed
between the six seroresponders with serological results indic-
ative of an acute infection only by rDNA LPS ELISA and the
other seroresponders. In addition, similar observations were
found when the clinical presentations of the seroresponders
and serononresponders were compared, although the severity
of the disease tended to be higher among seroresponders (data
not shown).
Different approaches were used to calculate the sensitivities
and specificities of the MIF assay, the rDNA LPS ELISA, and
PCR. When the MIF was used as the gold standard for the
diagnosis of an acute C. pneumoniae infection, the sensitivity
and specificity of the rDNA LPS ELISA were 80.0 and 94.3%,
respectively, while the sensitivity and the specificity of the PCR
were 46.7 and 83.0%, respectively (Table 2). A second gold
standard was incorporated to define more liberally the true-
positive patient population. A patient had true-positive results
if the MIF assay results were indicative of an acute C. pneu-
moniae infection or one or more respiratory specimens were
PCR positive. By using this expanded gold standard, the sen-
sitivities of the MIF assay and rDNA LPS ELISA were com-
parable (38.5 and 35.9%, respectively). Increased sensitivity
was now observed for the PCR (79.5%), but in this case all
respiratory specimens had to be processed (Table 2). Two
additional expanded gold standards, one more stringent and
the other more liberal but both serology based, were incorpo-
rated into the evaluation to determine the impacts of the
various gold standards (Table 2). Clearly, the sensitivity of the
PCR assay was substandard in the latter evaluation. The PPV
became clinically irrelevant.
Similar calculations were made to determine the impact of
specimen type on the sensitivity, specificity, NPV, and PPV
of the PCR (Table 3). Independent of the four different gold
standards used, the highest PCR sensitivity and specificity
could be obtained with nasopharyngeal specimens (Table 3).
Surprisingly, all sputum samples tested remained negative
(data not presented in Table 3).
The serological results for the first two serum samples were
used to determine the clinical value of a third serum sample
obtained after 30 days. The infections in only 67 and 75% of
FIG. 1. Schematic presentation of partially overlapping positive diagnostic
test results for acute C. pneumoniae respiratory infection in 156 patients with
CAP. n, MIF assay positive (n 5 15); h, rDNA LPS ELISA positive (n 5 20);
p, PCR positive (n 5 31).
TABLE 2. Sensitivity, specificity, NPV, and PPV of the rDNA LPS ELISA, MIF assay, and PCR for determination of
acute C. pneumoniae infections in patients with CAP requiring admission











MIF assay 15 (9.6) ELISA 80.0 94.3 97.8 60.0
PCR 46.7 83.0 93.6 22.6
Expanded gold standard 1a 39 (25.0) MIF 38.5 100.0 83.0 100.0
ELISA 35.9 94.9 81.6 70.0
PCR 79.5 100.0 93.6 100.0
Expanded gold standard 2b 12 (7.7) MIF 100.0 97.9 100.0 80.0
ELISA 100.0 94.4 100.0 60.0
PCR 41.7 81.9 94.4 16.1
Expanded gold standard 3c 23 (14.7) MIF 65.2 100.0 94.3 100.0
ELISA 87.0 100.0 97.8 100.0
PCR 39.1 83.5 88.8 29.0
a PCR and culture positive and/or MIF assay results indicating acute C. pneumoniae infection.
b MIF assay and rDNA LPS ELISA results indicating acute C. pneumoniae infection.
c MIF assay and/or rDNA LPS ELISA results indicating acute C. pneumoniae infection.
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the patients with serological results indicative of an acute in-
fection were diagnosed by the MIF assay and the rDNA LPS
ELISA, respectively, if only the first and second serum samples
were used for testing.
Since M. pneumoniae is a common agent in CAP and is a
well-known polyclonal B-cell activator (4), an attempt was
made to investigate the possibility of cross-reactivity in the
rDNA LPS ELISA due to acute M. pneumoniae infection.
Acute- and convalescent-phase serum samples from 40 pa-
tients with serological evidence of M. pneumoniae infection
were used for this evaluation. None of these patients had
serological results compatible with acute C. pneumoniae infec-
tion, as observed by the MIF assay and the rDNA LPS ELISA.
However, high prevalences of Chlamydia-specific IgG, IgM,
and IgA antibodies by rDNA LPS ELISA were found in these
patients (75, 18, and 48%, respectively). Positive results for
IgM were found for seven patients. However, all seven patients
had an IgM titer that was rather low (optical density values
ranged between 1.2 and 3.0 times the cutoff value, with a me-
dian valve of 1.5) and the titer did not change between the
acute and convalescent phases of their disease. To further elu-
cidate the nature of this IgM reactivity in these patients,
their serum samples were absorbed with a highly concentrated
M. pneumoniae suspension prior to their processing in the
ELISA. No significant reduction in Chlamydia-specific IgM
antibody titer was found after such absorption (data not
shown). Furthermore, the M. pneumoniae CF antibody titers in
the 156 patients with acute CAP were determined. These data,
together with those for patients with M. pneumoniae infection,
were analyzed. A positive correlation was found between the
Mycoplasma titer and the chlamydial IgG, IgM, and IgA sero-
prevalence, as determined by the rDNA LPS ELISA (Table 4).
DISCUSSION
More than 10 years after the first publication in 1986 sug-
gesting that C. pneumoniae causes acute respiratory infection
(22), the diagnosis of this infection is still difficult to make. In
the early 1970s, a sensitive MIF assay was developed, and this
assay proved to be suitable for routine diagnosis (49, 50). In the
MIF test, purified elementary bodies are used to detect Chla-
mydia-specific antibodies in the IgM, IgG, and IgA serum
fractions. Some researchers claim that the C. pneumoniae MIF
test is highly specific (22, 23, 36). Others, however, have noted
cross-reactions between C. pneumoniae and other chlamydial
species (31, 35, 37). This may be explained by the fact that the
elementary body of each Chlamydia species possesses both
genus-specific and species-specific antigenic sites. A species-
specific positive result is based on the reaction with the major
outer membrane protein of the elementary body, while chla-
mydial LPS is responsible for a genus-specific reaction (43).
Interpretation may thus be difficult. Also, rheumatoid factor
can cause false-positive C. pneumoniae IgM results (44). Acute
C. pneumoniae infections can also be diagnosed by culture and
PCR. However, these techniques require highly trained, expe-
rienced personnel and are not yet commercially available. Re-
cently, chemically pure chlamydial LPS has been applied in the
development of a commercially available rDNA LPS ELISA
(6, 7, 25). One of the disadvantages of using LPS is the inher-
ent serological cross-reactivity among the Chlamydia species.
However, a major advantage is the rapid development of anti-
LPS antibodies early in the infection (29). Also, the rDNA LPS
ELISA results are observer independent and can easily be
standardized for routine diagnosis, while interpretation of the
MIF assay results is more subjective and highly qualified per-
TABLE 3. Effect of specimen type on the performance of PCR for determination of acute C. pneumoniae infections
in 156 patients with CAP requiring admission











MIF assay 15 (9.6) Throat 20.0 89.9 91.2 17.6
Throat wash 6.7 95.6 90.3 14.3
Nasopharynx 40.0 89.9 93.3 30.0
Expanded gold standard 1a 39 (25.0) Throat 43.6 100.0 83.9 100.0
Throat wash 17.9 100.0 77.9 100.0
Nasopharynx 51.3 100.0 85.8 100.0
Expanded gold standard 2b 12 (7.7) Throat 16.7 89.4 92.7 11.8
Throat wash 8.3 95.7 92.4 14.3
Nasopharynx 33.3 88.7 94.0 20.0
Expanded gold standard 3c 23 (14.7) Throat 17.4 90.0 86.1 23.5
Throat wash 8.7 96.1 85.5 28.6
Nasopharynx 36.4 90.9 89.6 40.0
a PCR and culture positive and/or MIF assay results indicating acute C. pneumoniae infection.
b MIF assay and rDNA LPS ELISA results indicating acute C. pneumoniae infection.
c MIF assay and/or rDNA LPS ELISA results indicating acute C. pneumoniae infection.
TABLE 4. Correlation between M. pneumoniae antibody titer found
by CF antibody assay and Chlamydia-specific antibodies






No. (%) of patients seropositive
by rDNA LPS ELISA
IgGa IgMb IgAc
,4 35 19 (54) 2 (6) 18 (51)
4–16 69 35 (51) 8 (12) 37 (54)
32–128 69 43 (62) 11 (16) 40 (58)
$256 17 15 (88) 5 (29) 12 (71)
a Correlation coefficient, 0.902; P 5 0.098 (by chi-square test for trend, P 5
0.020).
b Correlation coefficient, 0.975; P 5 0.025 (by chi-square test for trend, P 5
0.020).
c Correlation coefficient, 0.954; P 5 0.049 (by chi-square test for trend, P 5
0.201).
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sonnel are required to interpret the fluorescence results. Little
is known about the sensitivity and specificity of this ELISA for
determination of the seroprevalence of C. pneumoniae. In this
study, we found that the rDNA LPS ELISA may not be reliable
for determination of the seroprevalence of C. pneumoniae, i.e.,
for use in searching for patients with serological evidence of a
C. pneumoniae infection in the past. The seroprevalence in the
two different patient populations indicates that the half-life of
the anti-LPS chlamydial antibodies is much lower than that of
the major outer membrane protein antibodies (this study). The
chlamydial LPS antibody seroprevalence was higher in patients
with a history of COPD than in blood donors. This may be
partly explained by differences in exposure between the two
study groups. Another explanation may be found in the co-
existence of other respiratory diseases in older adults with
COPD, which may, upon exposure to C. pneumoniae, predis-
pose them to clinical disease and thus result in an increased
C. pneumoniae seroprevalence (11, 24).
Another approach was to evaluate the MIF assay, CF test,
rDNA LPS ELISA, PCR, and culture for the diagnosis of CAP
caused by C. pneumoniae. However, the major problem in
validating these tests is the definition of the gold standard. By
using the MIF assay as the gold standard, the sensitivity, spec-
ificity, and, especially, the PPV of the rDNA LPS ELISA were
somewhat disappointing. Even more discouraging results were
observed by the CF test. The sensitivity of the CF test for the
detection of chlamydial infection was shown to be very low,
particularly for the elderly group of patients, in whom most
C. pneumoniae infections are reinfections that may not induce
complement-fixing antibodies. In the present study only two
patients had CF test results indicating acute chlamydial infec-
tion. Similar results were found earlier (13). The diagnostic
value of the CF test is therefore questionable, and clinicians
are dissuaded from making further use of the CF test for the
diagnosis of acute C. pneumoniae. Discouraging results were
also observed by PCR. This finding may in part be explained by
a low sensitivity of the MIF test. Only severe, deeper localized
infections may induce a reaction of the immune system. This is
one of the reasons that the utility of the MIF test for the
etiologic diagnosis of C. pneumoniae infection has been ques-
tioned earlier by several investigators (31, 37). Another ap-
proach that can be used to search for true-positive patients has
been published by Gaydos et al. (19) and Falck et al. (16). They
used an expanded gold standard that was based on MIF assay
serology and detection of the organism in respiratory speci-
mens. A patient was considered to be true positive if serolog-
ical evidence of an acute C. pneumoniae infection was observed
by the MIF assay or respiratory specimens were positive for
C. pneumoniae by PCR or culture. By using this expanded gold
standard, low sensitivities were found for the MIF assay and
the rDNA LPS ELISA. If all respiratory specimens were
incorporated in this evaluation, the highest sensitivity was
achieved by PCR. On the other hand, the use of PCR and
culture for the etiologic diagnosis of CAP caused by C. pneu-
moniae may be questioned. Asymptomatic C. pneumoniae in-
fections, which often have no serological response, have been
reported earlier (2, 14, 20, 26, 27), and this may affect the
specificity of the test. Therefore, we designed a more conser-
vative expanded gold standard, which validated the result for a
true-positive patient if the serological results obtained by the
MIF assay and the rDNA LPS ELISA indicated acute chla-
mydial infection. This will increase the probability of true
C. pneumoniae CAP. Again, the MIF assay and the rDNA LPS
ELISA performed equally well and were significantly better
than PCR. Either the MIF assay or the rDNA LPS ELISA
based on the last expanded gold standard definition on sero-
logical results indicating acute chlamydial infection. Increased
sensitivity was observed when the rDNA LPS ELISA was ap-
plied. Six patients had serological results indicative of an acute
infection only by rDNA LPS ELISA. This may be explained by
the difference in sensitivity which was reported earlier (47). In
addition, no clear difference in the clinical presentation be-
tween these six patients and the other seroresponders was
observed (data not shown).
Mixed infections in association with other agents were found
significantly more often in seroresponders than in serononre-
sponders. This may indicate that C. pneumoniae pneumonia
mixed with other etiologies may enforce the increased involve-
ment of the immune system due to more severe tissue damage.
Mixed infections with S. pneumoniae were most commonly
found. These findings were in accordance with the results of
Kauppinen and colleagues (29, 30) and Falguera and col-
leagues (17).
The choice of respiratory specimen may have a major impact
on the sensitivity of the C. pneumoniae PCR. Independently of
the four different gold standards used, the highest sensitivity
and specificity could be obtained with nasopharyngeal speci-
mens. Surprisingly, none of the sputum samples tested became
positive. These findings may indicate colonization of the or-
ganism in the upper respiratory tract rather than invasive in-
fection of the lower respiratory tract.
Only one patient was culture positive. This may be partly
explained by the cell line used. A previous investigation (45)
has indicated that BGM cells are highly sensitive for the iso-
lation and propagation of C. pneumoniae. However, the diag-
nostic value with patient samples was not previously evaluated.
Another possibility may be the cell culture protocol. Also, an
inapparent cell line contamination with Mycoplasma may con-
found research efforts (46).
Ekman et al. (13) demonstrated that the timing of retrieval
of the convalescent-phase serum sample is of great impor-
tance, because the MIF test may not show an increase in titer
until 4 weeks after infection. These results are in accordance
with our data; when the results for the third serum sample were
disregarded, the infection in 33 and 25% of the patients with
an established C. pneumoniae etiology was not diagnosed by
the MIF assay and the rDNA LPS ELISA, respectively. In
other words, the use of a third serum sample, drawn after 30
days, will maximize the ability to diagnose an acute infection
serologically. Also, the use of a single serum sample to diag-
nose an acute chlamydial infection may reduce the sensitivities
and specificities of the assays. Falck et al. (15) reported high
C. pneumoniae IgG antibody titers, as determined by the MIF
assay, in patients with persistent C. pneumoniae infection with-
out clinical signs of infection for periods of 6 months up to a
year. Also, persistent IgM for more than a year has been found
earlier (47). A chronic, asymptomatic C. pneumoniae infection
may be responsible for this phenomenon.
The increased prevalence of Chlamydia-specific antibodies
in patients with a recent M. pneumoniae infection found by the
rDNA LPS ELISA may be explained by polyclonal B-cell ac-
tivation. Polyclonal B-cell activation due to M. pneumoniae
infection has been reported earlier by Biberfeld and Gronow-
icz (4). The positive correlation found between the Myco-
plasma CF antibody titer and the Chlamydia-specific IgM prev-
alence may have a significant impact on the specificity of the
rDNA LPS ELISA, especially when a single serum sample is
used. None of these patients had significant changes in their
anti-LPS IgM titers. The use of paired serum samples from
each patient, taken with at least a 10-day interval, will negate
this problem.
In conclusion, the study shows that the choice of the gold
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standard remains difficult and, as expected, has a major impact
on the sensitivities and specificities of the tests validated in this
study. Further studies are necessary to determine the value of
the PCR with upper respiratory tract specimens to diagnose
lower respiratory tract infections. In addition, the rDNA LPS
ELISA may currently be the preferred serological tool for
diagnosing acute respiratory Chlamydia infections in routine
clinical practice. The presence of only C. pneumoniae DNA in
upper respiratory tract specimens, as demonstrated by PCR,
without a concomitant serological response, may indicate pro-
longed, harmless colonization of the respiratory tract rather
than the agent causing pneumonia.
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